- Home
- Aid by Sector
- Health
- Basic health
- Infectious disease control
Aid by Sector
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Accelerating Antibacterial Innovation with CARB-X
UK - Department of Health and Social Care (DHSC)
Through the Global AMR Innovation Fund (GAMRIF), the UK Department of Health and Social Care (DHSC) has invested £20 million over three years in Boston University’s Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), which is a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This contribution will invest in high-value, innovative research to accelerate the development of products to reduce the harm from drug-resistant infections. The aim of this project is to invest in high-value, innovative research to accelerate the development of products up to and including Phase I to reduce the harm to human health, welfare and economic growth from drug-resistant infections. In particular, the programme will focus on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in low- and middle-income countries (LMICs). Projects funded through GAMRIF will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with BactiVac
UK - Department of Health and Social Care (DHSC)
Vaccine Innovation with BactiVac is a partnership between the UK government and the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for AMR in humans and animals. The UK government has invested up to £1 million over one year into BactiVac, which is one of 5 networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research & Development. This is co-funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships, and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for antimicrobial resistance (AMR) for the benefit of people in low- and middle-income countries (LMICs). Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF)
UK - Department of Health and Social Care (DHSC)
Global Antimicrobial Resistance (AMR) Innovation Fund Programme
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in AMR Diagnostic Tools with FIND
UK - Department of Health and Social Care (DHSC)
FIND is a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support FIND’s work to enhance the impact of diagnostic tools for antimicrobial resistance (AMR), to support improved AMR surveillance and antibiotic stewardship. This work has two areas of focus: 1) to develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access of data; and 2) to develop a new diagnostic technologies for drug-resistant gonorrhea, which will enable improved diagnosis and therefore use of new antibiotics. Projects funded through GAMRIF will primarily benefit people in low- and middle-income countries, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - InnoVet AMR: Innovative Veterinary Solutions for AMR with IDRC
UK - Department of Health and Social Care (DHSC)
InnoVet-AMR is a partnership between DHSC and the International Development Research Centre (IDRC) aimed at reducing the emerging risk that antimicrobial resistance (AMR) in animals poses to global health and food security. InnoVet-AMR will fund research to develop new animal vaccines and other innovations to fight AMR in livestock (swine and poultry) and aquaculture production, particularly in low- and middle-income countries (LMICs). Through InnoVet-AMR, IDRC and DHSC aim to achieve two main objectives: (1) support research that will identify innovative veterinary solutions, including vaccines and alternative solutions, to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs; (2) build effective partnerships to better coordinate discovery, development and sustainable delivery of affordable innovative veterinary solutions to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs. Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
UK Vaccine Network - Vaccine Manufacturing Research Hubs Competition 2
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is collaborating with EPSRC (a nondepartmental public body principally funded through the Science Budget by the Department of Science, Innovation and Technology) in running the Vaccine Manufacturing Research Hubs competition. EPSRC has considerable expertise in running competitions in this nature. The Vaccine Manufacturing Research Hubs competition will be open to all eligible research organisations that can demonstrate that their work would contribute towards Vaccine Manufacturing Research. Successful projects will be awarded a research grant from EPSRC, mostly funded by DHSC.
UK Vaccine Network - UK Health Security Agency
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is making up to £3,100,000 available to the UK Health Security Agency (UKHSA) under the provisions of the International Development Act of 2002 to deliver a programme of seven projects that will advance vaccine development for diseases of epidemic potential for the benefit of people in low- and middle-income countries (LMICs). The programme will be wholly funded by DHSC through UK aid. The seven projects are: 1. CL4 Live Virus Neutralisation Tests; 2. Development of PNA Capability for Priority Pathogens; 3. Multiplex pAn-Virus Inhibition (MAVI) assays; 4. Preclinical model expansion for the assessment of cross-protective vaccines candidates against henipaviruses; 5. Development of GMP LassaVacc: Progression towards clinical trials; 6. Development of an X-ray inactivated whole virus vaccine for Zika and efficacy testing in an established rodent model; and 7. Advancement of a cost-effective MVA based Hantavirus vaccine (HantaVacc).
UK Public Health Rapid Support Team - Rapid investigation and response
UK - Department of Health and Social Care (DHSC)
"Created in 2016, the UK-PHRST is the primary arm of Her Majesty’s Government to provide and coordinate the UK’s public health response to outbreaks in LMICs. The UK-PHRST is a unique collaboration between Public Health England and the London School of Hygiene and Tropical Medicine with input from a number of academic partners. The UK-PHRST’s remit covers outbreak response, research, and capacity building, as components of its integrated triple mandate: • Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance (ODA), with the aim of stopping a public health threat from becoming a broader health emergency • Conduct research to generate an evidence base for best practice in epidemic preparedness and response • Build capacity for improved and rapid national response to disease outbreaks in LMICs and contribute to supporting implementation of IHR at the request of national governments or international stakeholders such as WHO. The UK-PHRST rapidly deploys a standing team of multidisciplinary public health professionals and researchers as required in countries that are a priority for the UK’s ODA programme. The UK-PHRST full-time Core Deployable Team consists of specialists in epidemiology, laboratory microbiology, infection prevention and control, clinical case management and clinical research, social science, data management and logistical support who are available to deploy within 48 of an approved request. Reservists and Field Epidemiology Training Programme (FETP) Fellows complement this team, providing surge capacity and specialist expertise when needed. The UK-PHRST is financed through UK Official Development Assistance (ODA) funding through the Department of Health and Social Care. The UK-PHRST Director is the accountable person to the UK Government, through PHE, for delivery of the UK-PHRST objectives." "The UK-Public Health Rapid Support Team is a key international partner in epidemic disease response. We partner with low- and-middle income countries to respond to infectious disease outbreaks before they can develop into global health emergencies. We work closely with international organisations, partner country governments and non-governmental organisations to: - Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance, with the aim of stopping a public health threat from becoming a broader health emergency - Conduct research to generate an evidence base for best practice in epidemic preparedness and response - Strengthen capacity for improved national response to disease outbreaks in LMICs We are an innovative partnership between the UK Health Security Agency and the London School of Hygiene & Tropical Medicine, funded with UK aid by the UK Department of Health and Social Care." The UK Public Health Rapid Support Team (UK -PHRST) has the following main objectives: 1) Within ODA eligible countries to support the rapid investigation and response to disease outbreaks at source, with the aim of stopping a public health threat becoming a health emergency. 2) Conduct rigorous research to aid epidemic preparedness and response and improve future response. 3) Generate an evidence base for best practice in disease outbreak interventions within ODA eligible countries. 4) Train a cadre of public health reservists for the UK -PHRST who can be rapidly deployed to respond to disease outbreaks. 5) Build capacity in-country for an improved and rapid national response to disease outbreaks and contribute to supporting implementation of the International Health Regulations (IHR).
UK Vaccine Network - Vaccines for epidemic diseases: readiness for clinical development and regulatory submission competition
UK - Department of Health and Social Care (DHSC)
The Project is a Small Business Research Initiative (SBRI), Official Development Assistance (ODA) competition funded by the Department of Health and Social Care (DHSC). The aim of the competition is to further invest in vaccines and vaccine technologies to address the 12 priority diseases (including Disease X) identified by the UK Vaccine Network. Proposals can address any part of the pre-clinical, non-clinical, manufacturing, or clinical pathway, within a 1-year time frame, making technology ready to be progressed further along the developmental pathway. This is a managed programme on behalf of DHSC. UKRI-Innovate UK are providing a fully managed end to end service. The call goes live on 4th October 2021. The SBRI contracts are required to be in place and live by 31 March 2022. Beneficiary Projects funded through this competition are required to primarily benefit ODA eligible countries, as per ODA policy.
UK Vaccine Network - Vaccine development for diseases with epidemic potential
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. DHSC is engaging Innovate UK (an Executive Non-Departmental Public Body established by the Higher Education and Research Act 2017) to run the Vaccine development for diseases with epidemic potential competition. Innovate UK are responsible for the delivery and management of this work on behalf of DHSC. DHSC is making up to £25,000,000 (twenty-five million pounds) available to Innovate UK under the provisions of the International Development Act of 2002 to run the Vaccine development for diseases with epidemic potential competition and fund the Successful Project(s).
UK Vaccine Network - Global Health Security and Medicines and Healthcare Products Regulatory Agency
UK - Department of Health and Social Care (DHSC)
The UK Department of Health and Social Care (DHSC) is collaborating with the Medicines and Healthcare products Regulatory Agency (MHRA) to deliver a programme of work consisting of two Work Packages, one with UKVN and the other with the Global AMR Innovation Fund (GAMRIF). The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. GAMRIF was established in 2016 in response to the Review on Antimicrobial Resistance chaired by Lord Jim O’Neill. It is a One Health UK aid fund that supports research and development (R&D) around the world to reduce the threat of antimicrobial resistance (AMR) in humans, animals and the environment by progressing therapeutics, preventatives and diagnostics along the pipeline for the benefit of people in low- and middle-income countries (LMICs). DHSC is making up to £2,700,000 available to the Partners under the provisions of the International Development Act of 2002 to manage and deliver the two Work Packages. Up to £1,000,000 of this will be for Work Package 1 (UKVN) and up to £1,700,000 for Work Package 2 (GAMRIF). The UKVN Work Package Supporting epidemic and pandemic preparedness by expanding the portfolio of research reagents for emerging viruses. Summary: Simple and timely access to high quality research reagents would accelerate the development of vaccines against emerging infectious diseases, particularly for scientists from low and middle-income countries (LMICs), which are frequently the worst affected. To meet this global need, we propose to expand the Centre for AIDS Reagents (CFAR) to become the Centre for Infectious Disease Reagents (CIDR). The existing CFAR repository at the Medicine and Healthcare products Regulatory Agency (MHRA), has successfully been providing a sustained research reagent resource to the scientific community since 1989, supplying more than 8500 vials of reagents to hundreds of organisations globally, in the past 10 years. Using our existing network and successful operating model, we would, with the expansion of scope for CIDR: Encourage leading laboratories to deposit state of the art research materials to our repository; Produce new reagents, primarily recombinant proteins and pseudotyped viruses; Commission new reagents from collaborators, including peptides and monoclonal antibodies. These materials will be prioritized to organisations in LMICs which will benefit from free of charge access. Our proven track record for collaboration, production and distribution of research reagents assures an ongoing legacy resource for research on emerging pathogens.
Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment
UK - Department of Health and Social Care (DHSC)
A grant to the Centre for Cellular and Mollecular Platforms (C-CAMP) to deliver a national and international call for application (‘AMR Challenge’) to identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of low- and middle-income countries(LMICs). The Challenge will be specific for AMR in the Environment and will be executed independently as curated and designed by GAMRIF and C-CAMP. However, through the broader umbrella of the India AMR Innovation Hub (Hub), anchored by C-CAMP, the larger stakeholder network may be leveraged for advancing the innovations identified through the Challenge.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - FAILSAFE ( Fungal AMR Innovations for LMICS): Solutions and Access For Everyone
UK - Department of Health and Social Care (DHSC)
This Programme will fund research and development of antifungal resistance products and solutions across the One Health spectrum, as well as deliver wider One Health and educational activities, to reduce the burden of fungal disease in low- and middle-income countries.
UK Vaccine Network - Coalition for Epidemic Preparedness Innovations
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid programme from the Department of Health and Social Care (DHSC). CEPI (the Coalition for Epidemic Preparedness Innovations) is a global public-private partnership established following the 2014-16 West-African Ebola epidemic to accelerate development of, and equitable access to, vaccines against emerging infectious diseases of epidemic and pandemic potential. It pools funding from sovereign donors and major philanthropic organisations to: (1) Support the advancement of vaccine candidates for known priority pathogens in low and middle-income countries; (2) Advance vaccine platform technology to support accelerated responses to an unknown pathogen (Disease X); and (3) Address key barriers to vaccine access in low- and middle-income countries, such as distribution of manufacturing capacity.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with the Bacterial Vaccinology Network (BactiVac)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for antimicrobial resistance (AMR) in humans and animals. BactiVac is one of five networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research and Development which is co-funded by the UK Medical Research Council (MRC) and the UK Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to accelerate the development of vaccines against bacterial infections, so that antimicrobial use in humans and animals is reduced in LMICs. This investment also supports new, diverse research projects to gain preliminary data and encourage new research partnerships, and allow these collaborations to build a track record, which will allow them to obtain further funding. It is expected that some of these projects will not yield expected research results, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early-stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for AMR for the benefit of people in LMICs.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid programme from the Department of Health and Social Care (DHSC) delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of antimicrobial resistance (AMR) in the environment. A national and international call for applications (‘AMR Challenge’) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of low- and middle-income countries (LMICs). The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub’s large stakeholder network may be leveraged to advance Challenge-funded innovations. Projects funded through the Global AMR Innovation Fund (GAMRIF) primarily benefit people in LMICs, where the burden of drug-resistant infection is greater. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Accelerating Antibacterial Innovation with Combating Antibiotic Resistant Bacteria Accelerator (CARB-X)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with Boston University’s Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This partnership will invest in high-value, innovative research to accelerate the development of products to reduce the harm to human health, welfare and economic growth from drug-resistant infections, up to and including Phase I. The programme will focus on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in LMICs.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - InnoVet AMR: Innovative Veterinary Solutions for Antimicrobial Resistance (AMR) with the International Development Research Centre (IDRC)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the International Development Research Centre (IDRC) and aims to reduce the emerging risk that antimicrobial resistance (AMR) in animals poses to global health and food security. InnoVet-AMR will fund research to develop new animal vaccines and other innovations to fight AMR in livestock (swine and poultry) and aquaculture production, particularly in LMICs. Through InnoVet-AMR, DHSC and IDRC aim to achieve two main objectives: (1) Support research that will identify innovative veterinary solutions, including vaccines and alternative solutions, to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs; and (2) Build effective partnerships to better coordinate discovery, development and sustainable delivery of affordable innovative veterinary solutions to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs. As part of the InnoVet-AMR programme, GAMRIF has also allocated additional funding to a partnership with the International Centre for Antimicrobial Resistance Solutions (ICARS). This complimentary research activity will support scoping and research projects focused on climate change, gender and equity in AMR mitigation.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in Antimicrobial Resistance (AMR) Diagnostic Tools with the Foundation for Innovative New Diagnostics (FIND)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Foundation for Innovative New Diagnostics (FIND), a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. Funding through GAMRIF will support FIND’s work to enhance the impact of diagnostic tools for AMR, improving AMR surveillance and antibiotic stewardship. This work has two areas of focus: (1) To develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access to data; and (2) To develop new diagnostic technologies for drug-resistant gonorrhoea, which will enable improved diagnosis and therefore use of new antibiotics.
UK Public Health Rapid Support Team (UK-PHRST) - Rapid Deployment and Capacity Strengthening
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC). The UK Public Health Rapid Support Team (UK-PHRST) is the primary mechanism for the UK Government to deploy technical expertise in outbreak response to ODA-eligible countries, stopping a public health threat from becoming a broader health emergency. It is a partnership between the UK Health Security Agency (UKHSA, formerly Public Health England (PHE)) and the London School of Hygiene and Tropical Medicine (LSHTM) and was established in 2016 in response to lessons learned from the West Africa Ebola outbreak. The UK-PHRST comprises public health experts who work to address the threat posed by infectious disease outbreaks in low- and middle- income countries (LMICs) through an integrated triple remit of: (1) Outbreak Response: Rapidly investigate and respond to disease outbreaks at source in LMICs to stop a public health threat from becoming a broader health emergency by deploying specialist public health experts; (2) Research: Deliver rigorous, collaborative research with partners to improve the evidence base for best practice in epidemic preparedness and response; and (3) Capacity Strengthening: Strengthen leadership, systems and technical capacity for an improved response to disease outbreaks in ODA-eligible countries.
Advanced filters
To search for Programmes in a specific time period, please enter the start and end dates.